SG&A Expense Trends: GSK plc vs Amicus Therapeutics, Inc.

In the ever-evolving pharmaceutical landscape, understanding the financial strategies of industry giants is crucial. Over the past decade, GSK plc and Amicus Therapeutics, Inc. have demonstrated contrasting trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, GSK's SG&A expenses have shown a relatively stable pattern, peaking in 2019 with a 14% increase from 2014, before slightly declining. In contrast, Amicus Therapeutics has experienced a dramatic rise, with expenses surging by over 1,200% during the same period. This stark difference highlights GSK's established market presence and Amicus's aggressive growth strategy. As GSK navigates the complexities of a mature market, Amicus's rapid expansion reflects its ambition to carve out a significant niche. These trends offer a fascinating glimpse into the strategic priorities of these pharmaceutical players, providing valuable insights for investors and industry analysts alike.